| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7967011 (Pediatric) | ASTRAZENECA | Inhalation device |
Feb, 2022
(1 year, 7 months ago) | |
| US7759328 | ASTRAZENECA | Composition for inhalation |
Jan, 2023
(8 months ago) | |
| US8575137 | ASTRAZENECA | Composition for inhalation |
Jan, 2023
(8 months ago) | |
| US10166247 | ASTRAZENECA | Composition for inhalation |
Jan, 2023
(8 months ago) | |
| US8143239 | ASTRAZENECA | Composition for inhalation |
Jan, 2023
(8 months ago) | |
| US11311558 | ASTRAZENECA | Composition for inhalation |
Jan, 2023
(8 months ago) | |
|
US11311558 (Pediatric) | ASTRAZENECA | Composition for inhalation |
Jul, 2023
(2 months ago) | |
|
US7759328 (Pediatric) | ASTRAZENECA | Composition for inhalation |
Jul, 2023
(2 months ago) | |
|
US8143239 (Pediatric) | ASTRAZENECA | Composition for inhalation |
Jul, 2023
(2 months ago) | |
|
US8575137 (Pediatric) | ASTRAZENECA | Composition for inhalation |
Jul, 2023
(2 months ago) | |
|
US10166247 (Pediatric) | ASTRAZENECA | Composition for inhalation |
Jul, 2023
(2 months ago) | |
| US8875699 | ASTRAZENECA | Inhaler cap strap |
Nov, 2024
(1 year, 1 month from now) | |
|
US8875699 (Pediatric) | ASTRAZENECA | Inhaler cap strap |
May, 2025
(1 year, 7 months from now) | |
| US7587988 | ASTRAZENECA | Inhaler device counter |
Apr, 2026
(2 years from now) | |
|
US7587988 (Pediatric) | ASTRAZENECA | Inhaler device counter |
Oct, 2026
(3 years from now) | |
| US8387615 | ASTRAZENECA | Inhaler cap strap |
Mar, 2027
(3 years from now) | |
|
US8387615 (Pediatric) | ASTRAZENECA | Inhaler cap strap |
Sep, 2027
(3 years from now) | |
| US8528545 | ASTRAZENECA | Inhaler device that reduces the risk for miscounting a dosage |
Oct, 2028
(5 years from now) | |
| US8616196 | ASTRAZENECA | Inhalation device and a method for assembling said inhalation device |
Apr, 2029
(5 years from now) | |
|
US8528545 (Pediatric) | ASTRAZENECA | Inhaler device that reduces the risk for miscounting a dosage |
Apr, 2029
(5 years from now) | |
|
US8616196 (Pediatric) | ASTRAZENECA | Inhalation device and a method for assembling said inhalation device |
Oct, 2029
(6 years from now) | |
Symbicort is owned by Astrazeneca.
Symbicort contains Budesonide; Formoterol Fumarate Dihydrate.
Symbicort has a total of 21 drug patents out of which 11 drug patents have expired.
Expired drug patents of Symbicort are:
- US7967011*PED
- US7759328
- US8575137
- US10166247
- US8143239
- US11311558
- US11311558*PED
- US7759328*PED
- US8143239*PED
- US8575137*PED
- US10166247*PED
Symbicort was authorised for market use on 21 July, 2006.
Symbicort is available in aerosol, metered;inhalation dosage forms.
Symbicort can be used as use for reducing exacerbations of chronic obstructive pulmonary disease; use for the treatment of asthma in patients 6 years of age and older; use for maintenance treatment of chronic obstructive pulmonary disease, use for the treatment of asthma in patients 6 years of age and older; use for maintenance treatment of chronic obstructive pulmonary disease; use for reducing exacerbations of chronic obstructive pulmonary disease, use for the treatment of asthma in patients 6 years of age and older; use for reducing exacerbations of chronic obstructive pulmonary disease; use for maintenance treatment of chronic obstructive pulmonary disease, use for reducing exacerbations of chronic obstructive pulmonary disease; use for maintenance treatment of chronic obstructive pulmonary disease; use for the treatment of asthma in patients 6 years of age and older.
The generics of Symbicort are possible to be released after 07 October, 2029.
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient
Market Authorisation Date: 21 July, 2006
Treatment: Use for the treatment of asthma in patients 6 years of age and older; Use for reducing exacerbations of chronic obstructive pulmonary disease; Use for maintenance treatment of chronic obstructive pulm...
Dosage: AEROSOL, METERED;INHALATION
SYMBICORT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic